A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid…

Overview of attention for article published in BMC Musculoskeletal Disorders, February 2016

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

twitter: 6 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 82 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 30,315 followers.

RT @RheumNow: Emery & colleagues plan to study rapidity/depth of remission of VERY early Enbrel (@1st visit) in early RA (VEDERA) https://t…

Reply Repost Favourite

RT @RheumNow: Emery & colleagues plan to study rapidity/depth of remission of VERY early Enbrel (@1st visit) in early RA (VEDERA) https://t…

Reply Repost Favourite

RT @RheumNow: Emery & colleagues plan to study rapidity/depth of remission of VERY early Enbrel (@1st visit) in early RA (VEDERA) https://t…

Reply Repost Favourite

RT @RheumNow: Emery & colleagues plan to study rapidity/depth of remission of VERY early Enbrel (@1st visit) in early RA (VEDERA) https://t…

Reply Repost Favourite

RT @RheumNow: Emery & colleagues plan to study rapidity/depth of remission of VERY early Enbrel (@1st visit) in early RA (VEDERA) https://t…

Reply Repost Favourite

Emery & colleagues plan to study rapidity/depth of remission of VERY early Enbrel (@1st visit) in early RA (VEDERA) https://t.co/UsoUlt9PoH

Reply Repost Favourite